Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Evogene Ltd.'s quarterly P/E stands at 0.6x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.29 | 0.65 | — | — | 7.44 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.86 | 7.96 | 2.62 | 0.87 | 1.97 | 2.56 | 13.67 | 2.27 | 18.38 | 1.91 | 18.49 | 10.19 | 109.33 |
| — | +210.8% | -80.9% | -61.6% | -89.3% | +34.4% | -26.0% | -77.8% | -83.2% | -99.0% | -92.7% | -98.2% | -79.9% | |
| P/B Ratio | 0.32 | 0.58 | 0.75 | 0.69 | 0.86 | 1.46 | 1.66 | 1.50 | 1.48 | 0.80 | 1.55 | 0.92 | 8.30 |
| — | -60.5% | -55.0% | -54.2% | -42.2% | +81.9% | +6.7% | +63.1% | -82.1% | -91.0% | -77.8% | -90.6% | -22.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 16.16 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Evogene Ltd.'s operating margin was -870.2% in Q3 2025, down 522.8 pp QoQ and down 530.0 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -419.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 243.7% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.8% | -40.4% | 51.8% | 10.3% | 16.3% | 28.1% | -10.1% | 76.6% | -83.6% | 68.9% | -69.4% | -50.2% | -52.3% |
| — | -243.7% | +613.9% | -86.6% | +119.5% | -59.2% | +85.5% | +252.5% | -59.9% | +207.4% | +61.5% | +80.4% | +68.0% | |
| Operating Margin | -255.4% | -870.2% | -347.4% | -176.6% | -283.5% | -340.2% | -764.3% | -85.1% | -1319.7% | -111.0% | -1208.1% | -1060.2% | -1103.3% |
| — | -155.8% | +54.5% | -107.5% | +78.5% | -206.4% | +36.7% | +92.0% | -19.6% | +92.7% | +52.9% | +68.8% | +60.5% | |
| Net Margin | -193.7% | 1241.7% | -504.8% | -105.9% | 26.5% | -438.5% | -895.7% | -92.2% | -1142.0% | -105.8% | -1073.9% | -978.3% | -454.2% |
| — | +383.2% | +43.6% | -14.8% | +102.3% | -314.6% | +16.6% | +90.6% | -151.4% | +92.5% | +62.0% | +72.0% | +80.8% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.8% | 26.2% | -36.0% | -19.0% | 3.2% | -47.4% | -23.9% | -14.3% | -20.5% | -11.9% | -23.6% | -19.8% | -8.2% |
| — | +155.1% | -50.7% | -33.0% | +115.4% | -298.6% | -1.5% | +27.9% | -149.3% | +23.9% | -33.7% | -41.5% | +25.3% | |
| ROA | -36.2% | 12.9% | -13.1% | -7.0% | 1.1% | -18.8% | -12.4% | -7.9% | -12.1% | -7.2% | -13.7% | -11.9% | -5.2% |
| — | +168.6% | -5.9% | +11.6% | +108.8% | -162.4% | +9.6% | +33.5% | -133.7% | +36.4% | +4.3% | -2.8% | +43.8% | |
| ROIC | -102.4% | -13.2% | -13.3% | -21.4% | -28.1% | -20.2% | -12.2% | -12.1% | -29.0% | -14.7% | -29.5% | -29.0% | -30.3% |
| — | +34.7% | -9.2% | -76.8% | +2.9% | -37.6% | +58.7% | +58.2% | +4.2% | +49.0% | +2.0% | -31.8% | -61.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 352.1% YoY to 4.92x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.87 | 0.15 | 1.03 | 1.05 | 0.87 | 0.90 | 1.08 | 0.45 | 0.40 | 0.32 | 0.38 | 0.42 | 0.34 |
| — | -83.8% | -5.3% | +134.0% | +116.3% | +179.7% | +185.2% | +6.6% | +17.0% | +3.3% | +712.8% | +816.7% | +714.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.15 | 4.92 | 1.89 | 1.06 | 1.15 | 1.09 | 1.58 | 5.06 | 4.96 | 6.25 | 5.59 | 5.86 | 6.71 |
| — | +352.1% | +19.1% | -79.1% | -76.7% | -82.6% | -71.7% | -13.7% | -26.0% | -14.4% | -17.9% | -22.7% | -18.8% | |
| Quick Ratio | 1.06 | 4.41 | 1.76 | 0.92 | 1.06 | 1.03 | 1.53 | 4.94 | 4.95 | 6.24 | 5.55 | 5.75 | 6.61 |
| — | +329.2% | +14.5% | -81.4% | -78.6% | -83.5% | -72.4% | -14.1% | -25.1% | -14.2% | -18.1% | -23.8% | -19.9% | |
| Interest Coverage | -175.27 | -5.99 | -4.89 | -9.30 | -31.72 | -2.05 | -47.67 | -21.49 | -107.44 | -38.38 | -31.99 | -12.63 | -44.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonEvogene Ltd.'s current P/E is -0.3x. The average P/E over the last 2 quarters is 4.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Evogene Ltd.'s current operating margin is -255.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Evogene Ltd.'s business trajectory between earnings reports.